Vivos Therapeutics, Inc. Cost of Revenue
Vivos Therapeutics, Inc. (VVOS) reported Cost of Revenue of $6.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2026-04-15
- Vivos Therapeutics, Inc. cost of revenue for fiscal 2025 was $6.90M, a 14.79% increase from fiscal 2024.
- Vivos Therapeutics, Inc. cost of revenue for fiscal 2024 was $6.01M, a 8.72% increase from fiscal 2023.
- Vivos Therapeutics, Inc. cost of revenue for fiscal 2023 was $5.53M.
| Period end | Cost of Revenue 12 month |
|---|---|
| 2025-12-31 | $6.90M 10-K · filed 2026-04-15 |
| 2024-12-31 | $6.01M 10-K · filed 2026-04-15 |
| 2023-12-31 | $5.53M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |